Literature DB >> 2077634

Defining treatment refractoriness in schizophrenia.

H Y Meltzer1.   

Abstract

The criteria for treatment refractoriness for the use of clozapine are necessarily set at a high level because of the potential risk of agranulocytosis with this treatment. However, a more liberal definition should be considered to better appreciate the limitations of current therapies and prepare for switching to the next generation of clozapine-like drugs that do not cause agranulocytosis. It is suggested that failure of therapy to bring about the best premorbid level of functioning be considered as a starting point for treatment-resistance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2077634     DOI: 10.1093/schbul/16.4.563

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  11 in total

1.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

2.  Combined Antipsychotics and Electroconvulsive Therapy in an Acutely Psychotic Patient with Treatment-resistant Schizophrenia.

Authors:  Ruth Rayikanti; Iga Lentowicz; Badari Birur; Li Li
Journal:  Psychopharmacol Bull       Date:  2017-05-15

Review 3.  Genetics of antipsychotic-induced side effects and agranulocytosis.

Authors:  Nabilah I Chowdhury; Gary Remington; James L Kennedy
Journal:  Curr Psychiatry Rep       Date:  2011-04       Impact factor: 5.285

4.  Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms.

Authors:  Michael Riedel; Norbert Müller; Martin Strassnig; Ilja Spellmann; Rolf R Engel; Richard Musil; Sandra Dehning; Anette Douhet; Markus J Schwarz; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-11-04       Impact factor: 5.270

Review 5.  Quantifying clinical relevance in the treatment of schizophrenia.

Authors:  Christoph U Correll; Taishiro Kishimoto; Jimmi Nielsen; John M Kane
Journal:  Clin Ther       Date:  2011-12       Impact factor: 3.393

6.  Concept and Management of Treatment Resistant Schizophrenia (TRS).

Authors:  Nitesh Painuly; Nitin Gupta; Ajit Avasthi
Journal:  Indian J Psychiatry       Date:  2004-04       Impact factor: 1.759

7.  Accessing Gene Expression in Treatment-Resistant Schizophrenia.

Authors:  Patricia N Moretti; Vanessa K Ota; Eduardo S Gouvea; Mariana Pedrini; Marcos L Santoro; Fernanda Talarico; Leticia M Spindola; Carolina Muniz Carvalho; Cristiano Noto; Gabriela Xavier; Elisa Brietzke; Ary Gadelha; Rodrigo Bressan; Jair Mari; Sintia Belangero
Journal:  Mol Neurobiol       Date:  2018-01-26       Impact factor: 5.590

8.  Treatment of the special patient with schizophrenia.

Authors:  R R Conley; D L Kelly
Journal:  Dialogues Clin Neurosci       Date:  2001-06       Impact factor: 5.986

9.  Treatment-refractory schizophrenia.

Authors:  Asaf Caspi; Michael Davidson; Carol A Tamminga
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

10.  Current perspectives in the treatment of resistant schizophrenia.

Authors:  R K Solanki; Paramjeet Singh; Deepti Munshi
Journal:  Indian J Psychiatry       Date:  2009 Oct-Dec       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.